Tickers

1. Composite Trajectory Verdict

Given HPQ’s hardware-and-services model with significant working‑capital intensity, all three statements carry roughly equal weight: the income statement shows whether pricing and cost actions are translating into profit, the cash flow statement reveals the sustainability of operations and shareholder returns, and the balance sheet reflects leverage, liquidity, and the negative equity position that constrains financial flexibility.

Composite Trajectory: Mixed

Revenue is growing (FY2025 +3.2% YoY; Q3 FY2026 +12.5% YoY; nine‑month FY2026 +9.5% YoY), but gross and net margins are compressing on both an annual and quarterly basis. Cash from operations was flat annually (FY2025 $3.70B vs FY2024 $3.75B) yet surged 47% in the most recent nine‑month period ($3.04B vs $2.07B). The balance sheet has strengthened — cash rose to $4.2B, total debt fell to $9.2B, and the stockholders’ deficit narrowed from –$1.3B to –$0.09B — while working‑capital metrics (DSO, DIO) have deteriorated. Improving dimensions: revenue growth, recent CFO surge, debt reduction, equity improvement. Deteriorating dimensions: margin compression, declining net earnings, rising receivables and inventory days.

2. Red Flags

• Gross margin compression: FY2025 gross margin 20.6% vs 22.1% in FY2024 (10-K FY2025, Consolidated Statements of Operations); Q3 FY2026 18.8% vs 20.5% in Q3 FY2025 (10-Q Q3 FY2026, MD&A).
• Net earnings decline despite revenue growth: FY2025 net earnings $2.53B vs $2.78B in FY2024 (10-K FY2025, Consolidated Statements of Operations); Q3 FY2026 $661M vs $763M in Q3 FY2025 (10-Q Q3 FY2026, MD&A); nine‑month FY2026 $1.66B vs $1.73B in prior year (10-Q Q3 FY2026, MD&A).
• DSO increase: FY2025 35 days vs 33 days in FY2024 (10-K FY2025, MD&A); Q3 FY2026 41 days vs 33 days in Q3 FY2025 (10-Q Q3 FY2026, MD&A).
• Inventory days increase: FY2025 66 days vs 63 days in FY2024 (10-K FY2025, MD&A); Q3 FY2026 73 days vs 68 days in Q3 FY2025 (10-Q Q3 FY2026, MD&A).
• Restructuring charges surge: nine‑month FY2026 $539M vs $302M in prior year, driven by Fiscal 2026 Plan EER program (10-Q Q3 FY2026, MD&A).
• Large uncertain tax positions: $865M at FY2025 (down from $1.22B) and $640M at July 31 2026 (10-K FY2025, Note 6; 10-Q Q3 FY2026, Contractual and Other Obligations).
• IEEPA tariff refunds recognized as cost reduction: $127M received in nine months FY2026, with $91M more subsequent (10-Q Q3 FY2026, Macroeconomic Environment).
• Non‑recurring litigation benefit in interest & other: $52M in FY2025 (10-K FY2025, Note 10) and a similar gain in Q3 FY2025 comparative period (10-Q Q3 FY2026, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Net earnings have fallen for two consecutive full fiscal years (FY2024 $2.78B → FY2025 $2.53B) and in the most recent comparable quarter (Q3 FY2026 $661M vs Q3 FY2025 $763M) and nine‑month period (FY2026 $1.66B vs FY2025 $1.73B). Gross margin contracted 1.5 pp annually and 1.7 pp in Q3, while operating margin fell annually (5.7% vs 7.1%) but ticked up in Q3 (5.7% vs 5.1%). Diluted EPS declined annually ($2.81 → $2.65) and is implied lower quarterly. The persistent margin compression alongside revenue growth indicates that cost increases (commodities, tariffs) and mix shifts are outpacing pricing actions.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow was essentially flat over three years (FY2023 $3.57B, FY2024 $3.75B, FY2025 $3.70B). However, the nine‑month period ending July 2026 shows a 47% jump in CFO to $3.04B from $2.07B in the prior year, driven by favorable working‑capital changes. Investing outflows dropped to $465M from $1.11B (lower CapEx and reduced collateral posting). Financing outflows rose to $2.12B from $1.34B due to higher debt repayments ($1.39B vs $0.21B) and share repurchases ($0.7B vs $0.3B implied). Free cash flow (CFO – CapEx) fell annually (FY2025 ~$2.8B vs FY2024 ~$3.2B) but likely improved in the nine‑month window given the CFO surge and lower CapEx.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Total assets grew 4.7% YoY to $41.8B (10-K FY2025, Consolidated Balance Sheets). Cash and equivalents rose from $3.24B to $3.69B at FY2025 and further to $4.17B at July 31 2026 (10-Q Q3 FY2026, Consolidated Balance Sheets). Total debt was stable at $9.67B at FY2025 and declined to $9.16B at July 31 2026 (short‑term debt up to $1.29B, long‑term down to $7.87B). The stockholders’ deficit narrowed from –$1.32B to –$0.35B at FY2025 and to –$0.09B at July 31 2026, reflecting retained earnings accumulation and other comprehensive income improvement. The cash conversion cycle remained stable at –37 days (10-Q Q3 FY2026, MD&A), though DSO and DIO increased while DPO rose more.

6. Data Gaps

• Quarterly diluted EPS for Q3 FY2026 and Q3 FY2025 (not disclosed in the provided 10‑Q excerpts).
• Standalone quarterly cash flow statements for Q1, Q2, and Q3 FY2026 (only nine‑month aggregates in the Q3 10‑Q).
• Segment‑level gross margins for quarterly periods (only segment revenue and earnings from operations provided).
• Quarterly free cash flow figures (CapEx not broken out by quarter in the filings provided).
• Detailed debt maturity schedule for the next 12 months (10‑K shows only aggregate future maturities by fiscal year).
• Comparative quarterly results for Q1 and Q2 FY2026 (only nine‑month cumulative data in the Q3 10‑Q).